This article is more than 5 years old. Information may no longer be current.
Travoprost superior to timolol in IOP lowering
Click Here to Manage Email Alerts
DALLAS — Travoprost dosed once daily in the evening was statistically significantly superior to timolol dosed twice daily, a multicenter study found. Over the course of the 6-month study, travoprost reduced intraocular pressure by up to 2 mm Hg more than timolol in patients with open-angle glaucoma or ocular hypertension.
Ronald Fellman, MD, and colleagues included in their study 605 patients who had open-angle glaucoma or ocular hypertension with an 8 a.m. IOP of between 24 mm Hg and 36 mm Hg in at least one eye. Patients were randomized to travoprost 0.0015% or travoprost 0.004% dosed once daily or to timolol 0.5% dosed twice daily.
Both concentrations of travoprost were statistically significantly superior to timolol in IOP lowering. At nine of 13 visits, patients taking the 0.0015% concentration of travoprost showed greater IOP reductions than patients taking timolol, ranging from 0.9 mm Hg to 1.8 mm Hg. At 10 of 13 visits, patients on travoprost 0.004% had IOP reductions of 0.9 mm Hg to 2.4 mm Hg greater than patients on timolol.
Incidence of hyperemia was higher in the travoprost group than in the timolol group, with 29% of patients on travoprost 0.0015%, 43% of patients on travoprost 0.004% and 9% of patients on timolol developing hyperemia.
A decrease in pulse and systolic blood pressure was observed in the timolol group as well.
The study is published in the May issue of Ophthalmology.